Chinese Clinical Oncology

• 论著 • Previous Articles     Next Articles

Prognostic analysis of metastatic non-small cell lung cancer patients treated with helical tomotherapy

LI Zhong, LI Jing, LI Zhiqiang, WANG Yan, ZHONG Yu,ZHANG Jinjian, WEN Ting,HOU Youxian,JIA Junsong,CHEN Jing,XU Yanhong   

  1. Helical Tomotherapy Cancer Center,General Hospital of Guangzhou Military Command of PLA
  • Received:2014-08-05 Revised:2014-11-14 Online:2015-02-28 Published:2015-02-28
  • Contact: LI Jing

Abstract: Objective To investigate the prognosis and influential factors in metastatic nonsmall cell lung cancer(NSCLC) treated with helical tomotherapy.
MethodsThe clinical data of fifty-one cases of metastatic NSCLC treated by helical tomotherapy technology were collected in our center, from June 2011 to February 2013. Radiation to all the target volume was delivered to a median dose of 42.5 Gy(30-62 Gy) with a median daily dose of 2 Gy(1.8-3 Gy). The Kaplan-Meier method was used for calculating overall survival rates. The Log-rank test was used for survival difference analysis. The Cox proportional hazards regression model was used for multivariate prognostic analysis.Results All the patients were followed up more than one year, the median survival time of fifty-one cases of metastatic NSCLC was 19.3 months, the 1-year survival rate was 64.7%. Univariate analysis showed that the higher KPS score, adenocarcinoma, prior chemotherapy, without liver metastases and the plan target volume(PTV) ≤1300 cm3 were favorable prognostic factors for survival time in all patients. Multivariate analysis showed that the KPS score, prior chemotherapy and PTV were independent prognostic factors for metastatic NSCLC patients.
Conclusion Helical tomotherapy may further prolong the survival time and improve the prognosis for metastatic NSCLC patients.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!